Kristin Abate - 15 Oct 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
Chief Accounting Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Kristin Abate
Issuer symbol
KPTI
Transactions as of
15 Oct 2025
Net transactions value
$0
Form type
4
Filing time
16 Oct 2025, 16:33:08 UTC
Previous filing
03 Oct 2025
Next filing
22 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Abate Kristin Chief Accounting Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON /s/ Nancy Smith as Attorney-in-Fact for Kristin Abate 16 Oct 2025 0002045943

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +12,799 +127% $0.000000 22,845 15 Oct 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as follows: 2,799 RSUs vest in two equal annual installments beginning October 31, 2026, and 10,000 RSUs vest 100% on October 15, 2026.